As of 2025-07-15, the EV/EBITDA ratio of 4D Molecular Therapeutics Inc (FDMT) is -0.30. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FDMT's latest enterprise value is 59.17 mil USD. FDMT's TTM EBITDA according to its financial statements is -196.04 mil USD. Dividing these 2 quantities gives us the above FDMT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.5x - 13.1x | 12.8x |
| Forward P/E multiples | 12.5x - 17.5x | 13.3x |
| Fair Price | (49.85) - (52.56) | (52.35) |
| Upside | -1298.4% - -1363.5% | -1358.4% |
| Date | EV/EBITDA |
| 2025-07-11 | -0.33 |
| 2025-07-10 | -0.35 |
| 2025-07-09 | -0.36 |
| 2025-07-08 | -0.32 |
| 2025-07-07 | -0.25 |
| 2025-07-03 | -0.32 |
| 2025-07-02 | -0.34 |
| 2025-07-01 | -0.30 |
| 2025-06-30 | -0.20 |
| 2025-06-27 | -0.23 |
| 2025-06-26 | -0.28 |
| 2025-06-25 | -0.28 |
| 2025-06-24 | -0.26 |
| 2025-06-23 | -0.21 |
| 2025-06-20 | -0.29 |
| 2025-06-18 | -0.29 |
| 2025-06-17 | -0.30 |
| 2025-06-16 | -0.35 |
| 2025-06-13 | -0.36 |
| 2025-06-12 | -0.38 |
| 2025-06-11 | -0.35 |
| 2025-06-10 | -0.38 |
| 2025-06-09 | -0.45 |
| 2025-06-06 | -0.35 |
| 2025-06-05 | -0.24 |
| 2025-06-04 | -0.22 |
| 2025-06-03 | -0.23 |
| 2025-06-02 | -0.20 |
| 2025-05-30 | -0.17 |
| 2025-05-29 | -0.20 |
| 2025-05-28 | -0.14 |
| 2025-05-27 | -0.13 |
| 2025-05-23 | -0.14 |
| 2025-05-22 | -0.17 |
| 2025-05-21 | -0.16 |
| 2025-05-20 | -0.23 |
| 2025-05-19 | -0.22 |
| 2025-05-16 | -0.13 |
| 2025-05-15 | -0.07 |
| 2025-05-14 | -0.06 |
| 2025-05-13 | -0.09 |
| 2025-05-12 | -0.10 |
| 2025-05-09 | -0.05 |
| 2025-05-08 | -0.08 |
| 2025-05-07 | -0.05 |
| 2025-05-06 | -0.05 |
| 2025-05-05 | -0.16 |
| 2025-05-02 | -0.21 |
| 2025-05-01 | -0.13 |
| 2025-04-30 | -0.12 |